arrow
A

Alona Muzikansky

Harvard Medical School
H指数:90
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer

TBCRC 035:标准剂量和减量剂量帕博西利与内分泌疗法联合治疗激素受体(HR)阳性既往治疗过的转移性乳腺癌的随机Ⅱ期药效学研究

2026-03-100
OAAI
Non-invasive Resonance Raman Spectroscopy provides an early estimation of depth in a pig model of multi-depth burns

非侵入式共振拉曼光谱技术可在多深度烧伤的猪模型中提供早期深度评估。

2025-11-050
OA
Psychosocial and NF-κB Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial

心理社会和NF-κB活性:压力管理与韧性训练(放松反应韧性计划,SMART-3RP)对MGUS和冒烟型多发性骨髓瘤患者的影响:一项随机等待列表对照试验

2025-07-180
PRE
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104

贝伐单抗对NF2相关性神经鞘瘤病中非靶点颅内脑膜瘤和非前庭神经鞘瘤的影响:NF104

2025-05-280
PRE
Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer

洛沙坦重新连接肿瘤免疫微环境并抑制IGF-1以克服卵巢癌对化学免疫疗法的抵抗力

2024-10-050
PRE
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial
2024-08-270
OAAI
Phase II study of cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma
2024-03-220
PRE
Clinical and Genomic Predictors of Adverse Events in Newly Diagnosed Glioblastoma
2024-01-223
PRE
Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
2023-06-168
OA
Study protocol for a hybrid type 1 effectiveness-implementation trial testing virtual tobacco treatment in oncology practices [Smokefree Support Study 2.0]

混合1型有效性的研究方案-肿瘤学实践中虚拟烟草治疗的实施试验 [无烟支持研究2.0]

2022-07-151
OAAI